Concepedia

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang, Cora N. Sternberg, Cezary Szczylik, Jakub Żołnierek, Christian Kollmannsberger, Sun Young Rha, Georg A. Bjarnason, Bohuslav Melichar,

The Lancet Oncology · 2014 · 263 citations · 28 references

DOIFull text

Open access

Concepts

References

28

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +11

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

, , +8

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1.6K citations · Full text

, , +17

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers et al. · Cancer Cell · 2005 · 1.6K citations · Full text

, , +16